Virus News and Research

Latest Virus News and Research

New atomic-level model helps explain how SARS-CoV-2 causes extensive lung damage

Scientists at the U.S. Department of Energy's Brookhaven National Laboratory have published the first detailed atomic-level model of the SARS-CoV-2 "envelope" protein bound to a human protein essential for maintaining the lining of the lungs.

8 Jun 2021

TSMC grant could boost TGen's efforts to track SARS-CoV-2 variants

The Translational Genomics Research Institute, an affiliate of City of Hope, today announced a substantial grant from Taiwan Semiconductor Manufacturing Co. Ltd., one of the world's largest manufacturers of computer chips, to help TGen sustain Arizona's fight against COVID-19.

8 Jun 2021

Increased primary healthcare need for up to six months in children post-COVID-19

A new medRxiv* preprint describes the increasing use of primary healthcare among these children even after the acute phase of COVID-19, with pre-schoolers showing the most prolonged rise in primary healthcare visits.

8 Jun 2021

SARS-CoV-2 immunity persists for up to 11 months after natural infection

The study, published in the Journal of Infectious Diseases, determined how circulating antibody levels change after being infected with SARS-CoV-2.

8 Jun 2021

COVID-19 projections after California's reopening

A new medrxiv* preprint shows how important equitable and widespread vaccination is in preventing a resurgence of cases and deaths once restrictions on social interactions are lifted.

8 Jun 2021

The potential of mRNA vaccines for a wide range of diseases

A new review article published in the journal Briefings in Functional Genomics focuses on the general characteristic features and mechanisms of mRNA vaccines. Further, this review has summarized the current progress of mRNA vaccines that have been developed for wide-ranging diseases, including COVID-19 disease.

8 Jun 2021

Vaccination after prior infection elicits broadly neutralizing antibodies to SARS-CoV-2

A new medrxiv* preprint reports on the current landscape of vaccine-induced antibodies in the United Kingdom.

8 Jun 2021

How SARS-CoV-2 variant B.1.1.7 adapted to evade innate immunity

Researchers in the United States and the UK have conducted a study showing how the B.1.1.7 (Alpha) lineage of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) adapted to suppress host innate immune responses in lung epithelial cells.

8 Jun 2021

Researchers identify a novel host-directed therapeutic approach to COVID-19

Researchers in the UK have demonstrated the potential of modulating the expression of angiotensin-converting enzyme 2 (ACE2) as a novel host-directed therapeutic approach to protecting against coronavirus disease 2019 (COVID-19).

8 Jun 2021

Cell-to-cell contact helps in spreading SARS-CoV-2, finds study

People aren’t the only ones who should be social distancing — new research shows our cells need to as well. Researchers from Ohio State University in Columbus, Ohio, USA, used in-culture techniques to confirm SARS-CoV-2 transmission via cell-to-cell contact.

8 Jun 2021

What lessons have we learned over a year into the COVID-19 pandemic?

One of the pressing questions scientists are currently trying to answer is whether the current vaccines will remain effective against the emerging SARS-CoV-2 variants of concern. A new piece of research has been published in the journal Biomedicines, which discusses the knowledge we have gained thus far and the questions that researchers should address in future work.

8 Jun 2021

Treating critically ill COVID-19 patients with non-altered umbilical cord stem cells increases survival

Critically ill COVID-19 patients treated with non-altered stem cells from umbilical cord connective tissue were more than twice as likely to survive as those who did not have the treatment, according to a study published today in STEM CELLS Translational Medicine.

8 Jun 2021

What is the role of monoclonal antibody therapy in treating COVID-19?

A new study has been published in the journal Vaccines that deals with the present state of research on using mAbs for the treatment of the COVID-19 disease. Many clinical trials are being conducted to evaluate the efficacy and safety of several newly designed mAbs. Some of the mAbs are directed towards immune system responses, i.e., non-SARS-CoV-2 specific mAbs, while others are devised to neutralize the SARS-CoV-2 protein structure, i.e., SARS-CoV-2 specific mAbs.

8 Jun 2021

Boeing tested air purifiers like those widely used in schools. It decided not to use them in planes.

Aerospace giant Boeing tested two kinds of ionization technologies — like those widely adopted in schools hoping to combat covid — to determine how well each killed germs on surfaces and decided that neither was effective enough to install on its commercial planes.

8 Jun 2021

Could the intranasal route be an alternate avenue of COVID-19 vaccination?

A new study has been published in the journal Vaccines that summarizes the history of vaccines, reviews the current progress in COVID-19 vaccine technology, and discusses the status of intranasal COVID-19 vaccines as a potential pathway to immunization.

8 Jun 2021

Researchers review environmental risk assessments for recombinant COVID-19 viral vector vaccines

In a recent review, published in the journal Vaccines, researchers in Belgium look at the recombinant viral vector-vaccine candidates that are primarily against SARS-CoV-2 still in development and discuss their features from an environmental risk point of view.

8 Jun 2021

Mass vaccination the only way to tackle emerging SARS-CoV-2 variants

Researchers from Poland recently analyzed key information concerning SARS-CoV-2 variants, such as their infectivity, mutations, severity, and immune susceptibility. Their work is published in the open-access journal Pathogens.

8 Jun 2021

Nanozymes to the rescue - potential role in fighting COVID-19

Over the last few decades, researchers have developed artificial enzymes for many applications. Recently, they deployed nanomaterial-based enzyme mimetics or nanozymes in diagnosis and therapeutics. Nanozymes find applications in various biomedical applications, including antiviral agents and cancer therapy.

8 Jun 2021

NIH researchers identify novel small molecule inhibitors of SARS-CoV-2 variants

A team of scientists from the National Institutes of Health (NIH), USA, has recently identified six novel small molecule inhibitors of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its variants. The study is currently available on the bioRxiv* preprint server.

8 Jun 2021

Novel COVID-19 vaccine is safe, generates immune response in healthy adults

The COVID-19 pandemic continues to disrupt and end lives around the world, and public health officials worldwide have recognized vaccines as the critical tools required for controlling the COVID-19 death toll and achieving a return to normal life.

8 Jun 2021